Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$60.1 million.

  • Nurix Therapeutics' Free Cash Flow fell 34.97% to -$60.1 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$241.4 million, marking a year-over-year decrease of 125.79%. This contributed to the annual value of -$181.9 million for FY2024, which is 102.59% down from last year.
  • Per Nurix Therapeutics' latest filing, its Free Cash Flow stood at -$60.1 million for Q3 2025, which was up 8.72% from -$65.8 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Free Cash Flow ranged from a high of $24.1 million in Q4 2023 and a low of -$65.8 million during Q2 2025.
  • Over the past 3 years, Nurix Therapeutics' median Free Cash Flow value was -$44.8 million (recorded in 2024), while the average stood at -$42.0 million.
  • In the last 5 years, Nurix Therapeutics' Free Cash Flow plummeted by 739.42% in 2022 and then soared by 159.49% in 2023.
  • Nurix Therapeutics' Free Cash Flow (Quarterly) stood at -$31.8 million in 2021, then decreased by 27.53% to -$40.5 million in 2022, then soared by 159.49% to $24.1 million in 2023, then tumbled by 310.99% to -$50.9 million in 2024, then plummeted by 34.97% to -$60.1 million in 2025.
  • Its last three reported values are -$60.1 million in Q3 2025, -$65.8 million for Q2 2025, and -$64.6 million during Q1 2025.